ArticleJBMR plus2025
Romosozumab significantly improves vertebral cortical bone mass and structure compared with teriparatide, whereas both treatments increase vertebral trabecular bone mass similarly: high-resolution quantitative computed tomography analyses of randomized controlled trial results in postmenopausal women with low bone mineral density.
Article in JBMR plus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00896532 (A Randomised, Placebo-controlled, Multi-dose Phase 2 Study to Determine the Efficacy, Safety and Tolerability of AMG 785 in the Treatment of Postmenopausal Women With Low Bone Mineral Density), which is not on this map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomised, Placebo-controlled, Multi-dose Phase 2 Study to Determine the Efficacy, Safety and Tolerability of AMG 785 in the Treatment of Postmenopausal Women With Low Bone Mineral Density
Who cites it
5 citing papers in PubMed.
- Effects of romosozumab on the peripheral and axial skeleton in postmenopausal women at high fracture risk: real-world evidence from DXA and HR-pQCT data.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026Article
- Author response to the letter to the editor regarding "Hip Response to Romosozumab in Glucocorticoid Users: Beyond Systemic Bone Turnover Markers".Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026Article
- Very short-term monitoring of Romosozumab longitudinal effects in a cohort of postmenopausal women by means of Radiofrequency Echographic Multi-Spectrometry (REMS) technology.Aging clinical and experimental research · 2026Article
- A new age of osteoanabolic therapy? A real-world, two-centre study comparing effects of romosozumab, teriparatide, and antiresorptive therapies for osteoporosis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026Article
- Assessing cortical bone changes with Romosozumab after one year: Insights from an exploratory HR-pQCT study.Bone reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Romosozumab, a sclerostin inhibitor, exerts a dual effect of increasing bone formation while decreasing bone resorption to rapidly increase bone mineral density (BMD) and reduce fracture risk in postmenopausal women. Iterative Convolution OptimizatioN (ICON) allows accurate calculation of deconvolved cortical thickness from high-resolution quantitative computed tomography (HR-QCT) scanning. This study employed HR-QCT to evaluate compartmental (including endosteal and periosteal) changes in the vertebral cortical shell in postmenopausal women who received romosozumab, teriparatide, or placebo. In a subset of a phase 2, randomized study (NCT00896532), women (55-85 yr) with low BMD (T-score ≤ -2.0, but not <-3.5, at the lumbar spine, total hip, or femoral neck) treated with subcutaneous (SC) romosozumab monthly (210 mg;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.